• AAPL 167.04
  • TSLA 149.9
  • AMZN 179.17
  • MSFT 404.33
  • INTC 35.04
  • EURUSD 1.0648
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. TA /
  3. BONS.TA

Bonus Biogroup (BONS TA) stock market data APIs

ILA16.7 0.4(2.5%) as of April 18, 2024

Bonus Biogroup Financial Data Overview

16.3
16.7
-
16.7
16.3
14.1-32
190 M
1 168 M
0
1.121
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BONS',
Type: 'Common Stock',
Name: 'Bonus Biogroup',
Exchange: 'TA',
CurrencyCode: 'ILA',
CurrencyName: 'Israeli Agora',
CurrencySymbol: 'ILA',
CountryName: 'Israel',
CountryISO: 'Il',
OpenFigi: NULL,
ISIN: 'IL0004850116',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Bonus Biogroup Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -27 029 000
  • Earnings Per Share -0.05
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Bonus Biogroup Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get Bonus Biogroup End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Bonus Biogroup latest news via APIs

‏Bonus BioGroup's COVID Drug - MesenCure - Can Help a Life-threatening Complication Seen in Cancer Patients

Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, has discovered that its C...
  • BIOLOGICAL TREATMENTS
  • BONUS BIOGROUP
  • CANCER PATIENTS
  • COVID
  • ONCOLOGICAL PATIENTS
  • OVERREACTION
  • PRECLINICAL TRIAL

POET Technologies to Report Full Year 2021 Financial Results on April 26

POET Technologies Inc. Management to Host Business Update Conference Call on April 27 TORONTO, April 21, 2022 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Ventur...
  • COMPANY
  • CONFERENCE ID
  • OPTICAL INTERPOSER
  • POET TECHNOLOGIES INC
  • THE COMPANY
  • THOMAS MIKA
Do you have any questions?
support@eodhistoricaldata.com